Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Biophotonic Device Gets FDA Clearance
Jan 2013
TUSTIN, Calif., Jan. 7, 2013 — BioPhotas Inc.’s patented biophotonic medical device Celluma has received FDA clearance for six separate indications for use.

Celluma — LED technology based on NASA and DARPA research — uses three distinct wavelengths of light energy, modulated with proprietary electronic algorithms to effectively treat a variety of skin, muscle and joint conditions. It has received clearance to treat acne, muscle and joint pain, muscle spasms, arthritis, muscle and joint stiffness, and compromised local blood circulation.

LED, or biophotonic, therapy has been scientifically proven in recent clinical trials to noninvasively “re-energize” cellular function in the treatment of many common conditions, restoring the body’s natural ability to heal itself, according to NASA and DARPA research.

“Receiving FDA clearance for six separate indications for use is a major milestone for us in the development of our product portfolio and the growth of the company,” said President and CEO Patrick Johnson. “Our goal in developing the Celluma was to create a safe, effective and convenient device that could be used in the home and in a professional medical setting.”

BioPhotoas develops devices for health-care providers and consumers to treat a variety of pain, dermatology and musculoskeletal conditions.

For more information, visit:

acne treatmentAmericasBioPhotasBiophotonicsblood circulationBusinessCaliforniacellular functionsCellumaDARPAFDA clearancejoint and muscle painlight sourceslight-emitting diodesNASAPatrick JohnsonLEDs

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,
x We deliver – right to your inbox. Subscribe FREE to our newsletters.